Metastatic progression following multimodal therapy for unfavorable-risk prostate cancer

David Guy¹; Rachel Glicksman²; Roger Buckley³; Patrick Cheung²; Hans Chung²; Stanley Flax³; David Hajek³; Andrew Loblaw²; Gerard Morton²; Jeffery Noakes³; Les Spevack³; Joseph Chin¹; George Rodrigues¹
¹London Health Sciences Centre, London, ON, Canada; ²Sunnybrook Health Sciences Centre, Toronto, ON, Canada; ³North York General Hospital, Toronto, ON, Canada

Acknowledgements: This research was supported by the Ontario Graduate Scholarship program.

Cite as: Guy D, Glicksman R, Buckley R, et al. Metastatic progression following multimodal therapy for unfavorable-risk prostate cancer. Can Urol Assoc J 2021 November 18; Epub ahead of print. http://dx.doi.org/10.5489/cuaj.7525

Published online November 18, 2021

Corresponding author: Dr. David Guy, London Health Sciences Centre, London, ON, Canada; d.zekeguy@gmail.com

***

Abstract

Introduction: Identifying the optimal management of unfavorable-risk (ProCaRS high intermediate-, high-, and very high-risk categories) non-metastatic prostate cancer is an important public health concern given the large burden of this disease. We compared the rate of metastatic progression-free survival among men diagnosed with unfavorable-risk non-metastatic prostate cancer who were initially treated with radiation therapy or radical prostatectomy.

Methods: Information was obtained from medical records at two academic centers in Canada from 333 men diagnosed with unfavorable-risk non-metastatic prostate cancer between 2007 and 2012. Median followup was 90.4 months. Men were eligible for study if they received either primary radiation therapy (n=164) or radical prostatectomy (n=169), in addition to various adjuvant and salvage therapies when deemed clinically appropriate. Patients were matched on prognostic covariates using two matching techniques. Multivariable Cox proportional hazards models were used to estimate the hazard ratios (HR) and confidence intervals (CI) for metastatic progression-free survival between groups.

Results: After matching, treatment groups were balanced on prognostic variables except for percent core positivity. Hazard ratios from all Cox proportional hazards models (i.e., before and
after matching, and with and without multivariable adjustment) showed no difference in the rate of metastatic progression-free survival between groups (adjusted unmatched HR 1.16, 95% CI 0.63, 2.13, \( p=0.64 \)).

Conclusions: Metastatic progression-free survival did not differ between men diagnosed with unfavorable risk non-metastatic prostate cancer who were treated with either radiation therapy or radical prostatectomy.

Introduction
Prostate cancer (PCa) is a leading cause of cancer morbidity and mortality.\(^2\) Unfavorable risk non-metastatic disease, including unfavorable intermediate-, high- and extremely high-risk disease,\(^2\) accounts for approximately one third of all PCa diagnoses, but a disproportionate amount of morbidity and mortality.\(^3\) Optimizing the safety and efficacy of treatments for this disease is thus a major public health concern. Common definitive management options include radical prostatectomy (RP) and prostate radiotherapy (RT). Compared to watchful waiting and active surveillance, definitive management with RT and androgen deprivation therapy (ADT) or RP among men diagnosed with localized PCa has been shown in RCTs to improve oncological outcomes and survival.\(^4\)-6

The selective use of adjuvant and salvage therapies alongside definitive management has also been shown to further improve outcomes. The use of adjuvant RT for adverse pathological findings post-RP has been found to decrease biochemical recurrence.\(^7\) The addition of ADT to RT post-RP has been shown to further reduce rates of metastatic progression and PCa-specific mortality among those with adverse pathological features. The addition of adjuvant ADT alongside RT for patients with unfavorable-risk PCa has demonstrated decreased PCa-specific mortality.\(^8\) Results from the ASCENDE-RT trial have also shown improvements in biochemical control from combination external beam RT (EBRT) with BT compared to EBRT alone.\(^9\)

Finally, RT dose-escalation protocols have demonstrated improvements in biochemical control.\(^10\)

Despite the progress made in the selection and sequencing of adjuvant and salvage therapies and refinements in RT approaches, optimal initial treatment between RP and RT has not been adequately evaluated through a RCT for this population of unfavorable-risk patients. In turn, in the absence of specific patient- or tumor-factors influencing treatment decision, clinicians and patients rely on evidence generated from observational data to guide treatment decisions, which have limitations due to confounding and comparisons involving outdated treatment regimens. For example, RP compared to RT candidates generally have less aggressive tumor characteristics, are younger and have fewer comorbidities.\(^11\) Such disparities make statistical assumptions of positivity required for valid estimation of treatment effects.
questionable. As such, identifying patients treated with RP and RT who have similar baseline characteristics and who have undergone more contemporary forms of treatment is necessary to improve the internal and external validity of evidence in this area.

Herein, we compared the rate of metastatic-progression between men diagnosed with unfavorable-risk non-metastatic PCa and initially treated with RT and RP. Data were obtained from a multidisciplinary clinic wherein RT patients were also eligible for RP during the same clinical encounter to mitigate violations of positivity. Furthermore, we took advantage of novel matching strategies to improve the degree of comparability between treatment groups.

Methods

Data
Both institutional review boards at Sunnybrook Health Sciences Centre and London Health Science Centre (LHSC) provided ethics approval. We identified men diagnosed between 2007-2012 with unfavorable-risk non-metastatic PCa in the multi-disciplinary diagnostic assessment program in the Gale and Graham Wright Prostate Centre (GGWPC) in Canada. Patients in the RT group included those who had undergone EBRT with or without brachytherapy boost (BT) and with or without ADT. Patients in the RP group included those who had undergone RP as their primary treatment modality. Due to limited RP observations from the GGWPC, we also included men diagnosed between 2007-2012 with unfavorable-risk non-metastatic PCa who were treated with primary RP at LHSC in Canada.

Data collection
We reviewed electronic medical records from identified patients. Patient age at diagnosis, biopsy date, prognostic factors at diagnosis (pre-biopsy PSA level, TNM stage, Gleason Score (GS), and biopsy core involvement), initial treatment decision, treatment date, and treatment details were obtained. Patients were eligible for the study if they met the following criteria:

1. Diagnosed with ProCaRS unfavorable intermediate-, high- or extremely high-risk PCa.¹²
2. No evidence of regional or metastatic disease
3. Consulting Radiation Oncologist offered RT
4. Consulting Urologist offered RP
5. Diagnosed between July 2007 and December 2012
6. Had ≥ 1 year of follow-up

ProCaRS unfavorable intermediate-risk disease entails a GS=7 and one or both of PSA 10-20 ng/mL and/or bilateral clinical disease. High-risk disease entails a PSA>20 ng/mL, cT stage=3-4 or GS=8-10, while extremely high-risk disease entails a PSA>30 ng/mL or high-volume disease, defined as >87.5% biopsy core involvement. Information on patient comorbidities, socioeconomic and demographic characteristics were not available for the
majority of patients so were not collected. RT following RP was categorized as salvage if it was administered >6 months after RP or in response to a rising PSA; otherwise, it was categorized as adjuvant.

**Outcomes**
We analyzed the rate of metastatic progression-free survival between treatment groups. Metastatic progression was confirmed through imaging reports. Survival time was defined as the interval between the date of PCa treatment and the date of metastatic progression or last follow-up. Patients who were event-free at the end of the study period were censored and contributed the time interval from treatment date to the end of the study for the survival analysis.

**Covariate selection**
We explored the potential for confounding through examining differences between treatment groups in distributions of baseline covariates that have demonstrated a prognostic role in relation to the rate of treatment failure in previous literature. Covariates included tumor characteristics (i.e., pre-biopsy PSA level, clinical T (cT) stage, and GS). Age was not included as a covariate since it did not demonstrate a notable association with the outcome examined. Further, age was strongly associated with treatment choice, which would bias effect estimates if adjusted for. An insufficient number of patients had information on biopsy core involvement, so this variable is only reported in the descriptive statistics and not used for adjustment. However, point estimates of the hazard ratios did not notably differ when this variable was included.

**Propensity score matching**
The propensity score model was a logistic model with prognostic characteristics as independent variables and treatment received as a binary dependent variable. We explored interactions and non-linearity for baseline covariates when developing the propensity score model. Locally weighted scatterplot smoothers were used to assess for departures from linearity in the relationship between baseline PSA and the log odds of the probability for receiving RP. Improvements in the model fit were assessed using the likelihood-ratio test and pseudo-$R^2$. DFBETA statistics did not reveal any outliers. Model one involved baseline PSA as a linear term and cT-stage and GS as categorical variables. A restricted cubic spline with four knots was found to improve model fit for baseline PSA, and thus was included in model two. Participants were matched in a 1:1 ratio between treatment groups. We explored a range of caliper widths between 1.0 and 0.01 standard deviations of the logit of the propensity score. Nearest-neighbour matching was used without replacement.

**Coarsened exact matching**
Patients were matched on progressively coarsened covariates. GS was first dichotomized into ≤7 or 8-10 and then using each category. Clinical T-stage was first dichotomized into ≤2 and 3-4
and then using each category. Progressive coarsening for PSA involved cut points from 0 ng/ml to 300 ng/ml first at 20 and 100 ng/ml, with additional cut points at 30 and 50 ng/ml and further at 6 and 10 ng/ml. Coarsening ranges are presented in Table E1.

Balance diagnostics
We chose four balance measures that considered different data characteristics in order to monitor improvements in balance when further restricting matching strategies. This enabled systematic identification of matching strategies that optimized balance in the distribution of baseline covariates as a function of data retention. This process is shown in Figures E1&2.

Descriptive statistics and multivariable regression analysis
All statistical analyses were performed using RStudio version 3.6.0. Descriptive statistics were calculated for each treatment group before and after matching. Cox proportional-hazards regression analyses for estimating the effect of treatment group on the hazard of metastatic progression were performed using the Survival package. The proportional-hazards assumption was confirmed using log-minus-log survival plots and scaled Schoenfeld residuals. Improvements in model fit were examined through informally comparing the model log likelihoods after incorporating interaction terms and higher order terms and transformations for continuous covariates. Examination of a plot of DBETA statistics did not identify any influential observations. Hazard ratios and 95% confidence intervals were estimated from unmatched data both without and with adjustment for baseline PSA, cT stage, and GS as well as interactions between baseline PSA and GS and baseline PSA and cT stage. For matched data, we employed Cox models clustered by the matched sets with associated weights to account for variable matching ratios, using robust variance estimators to generate confidence intervals.

Results
Descriptive characteristics are displayed in Table 1. At diagnosis, men treated with RT relative to RP were older, had higher PSA levels, a greater percentage of tumor containing biopsy cores, less advanced tumor staging, and comparable GS. A greater proportion of men treated with RT presented with high-intermediate risk, and a smaller proportion of high-risk disease than those treated with RP, while similar proportions of each treatment group were considered extremely high-risk disease. Some RP patients met risk criteria but were unable to be categorized more specifically as either high- or extremely-high risk.

Treatment characteristics are displayed in Table 2. Among men treated with RT relative to RP, a greater proportion received neoadjuvant ADT and a smaller proportion received adjuvant ADT. Approximately one third of men in the RP group received local and systemic salvage therapy, while less than 10% of men treated with RP received systemic salvage therapy aside from adjuvant ADT. The most common form of RT was EBRT without BT boost, with a median dose for men of 78 Gy. Of those who received BT boost, the vast majority received
HDR, while only one man received LDR. Finally, two men treated with RT received SBRT boost. The median dose for patients treated with either a BT or SBRT boost was 113.57 Gy.

Descriptive characteristics after matching are displayed in Table 3. After propensity score matching, 117 subjects were retained in each group, while coarsened exact matching led to retention of 138 and 141 patients from the RT and RP groups, respectively. Both matching strategies led to balance in the multivariable covariate structure according to conventional thresholds for balance (i.e., SMD<0.1 and variance ratio between 0.92 to 1.08).10 Age and mean percent of tumor containing biopsy cores remained imbalanced.

Kaplan-Meier curves showing the probability of metastatic progression-free survival over time stratified by treatment group are shown in Figure 1. Median follow-up time for censored patients was approximately 93.6 months. Overall, both groups demonstrated similar rates of metastatic progression-free survival and unadjusted and adjusted hazards ratios and 95% confidence intervals before and after matching demonstrated no significant difference (Table 4).

Discussion
We compared the rate of metastatic progression between men diagnosed with unfavorable-risk non-metastatic PCa who were treated with RT or RP. No significant difference was observed in the rate of metastatic progression between treatment groups. Previous reports have demonstrated reduced rates of metastatic progression among men diagnosed with unfavorable-risk non-metastatic PCa who were treated with RT compared to RP.21-23 This includes a study of men diagnosed with NCCN high- and very high-risk PCa in a multidisciplinary clinic and treated with RT or RP wherein rates of distant metastasis were insignificantly elevated among those treated with RP relative to those treated with RT (HR [95%CI]: 2.5 [0.8, 7.8]; p=0.11).23 These findings are consistent with another comparison of metastatic progression between men diagnosed with unfavorable-risk PCa and treated with EBRT+ADT relative to RP.22 The null finding in our study might be attributable to the low rate of ADT administration (57.9%) compared to the much higher rate used in other studies (approximately 100%).

Substantial variation in oncological outcomes has also been observed with the use of combination EBRT+BT relative to EBRT alone. For instance, lower rates of metastatic progression have been found among men diagnosed with unfavorable-risk non-metastatic PCa and treated with combination EBRT+BT relative to RP (0.27 [0.17, 0.43]).21 This finding is consistent with other reports demonstrating improved PCa-specific survival among combination EBRT+BT relative to EBRT alone.24,25 In the current study, few men (11.2%) received combination EBRT+BT, preventing subgroup comparisons.

The rate of salvage therapy post-RP was much higher than that post-RT. Local and systemic salvage therapy were administered to approximately 30% of men post-RP, while only about eight percent treated with RT received salvage therapy. These observations are consistent with previous investigations by Kishan et al who found similar rates of local and systemic
salvage therapy post-RP,\textsuperscript{21} and Markovina et al who found salvage much more common post-RP than post-RT.\textsuperscript{22} This can, in part, be explained by the increased rates of biochemical-failure among men diagnosed with unfavorable-risk non-metastatic PCa who undergo RP relative to RT. Administration of salvage therapy is also less standardized among men with biochemical-failure post-RT. Since men who undergo RT are generally older, with poorer health and lower life expectancies, the options and potential benefits of salvage therapy may be limited, with potential for adverse impact on quality of life from associated side effects. Moreover, the rate of salvage local therapy post-RT might be hampered due to limited availability and awareness of modalities such as cryotherapy and high intensity focused ultra-sound, although the number of patients with local failure only post-RT is not known for this cohort.

The median follow-up time was 13 months shorter in the RT relative to the RP group. This might be explained by increased rates of competing events that would increase losses to follow-up. To explain, those receiving RT were also approximately 10 years older than those receiving RP and likely had increased comorbidities. During later phases of PCa management, competing illnesses that decrease life-expectancy may take priority and patients might stop attending follow-up appointments for their PCa if it poses less threat to their survival. Unfortunately, data from other clinics indicating development of metastasis was not available, preventing competing risks analyses. This missing data issue can bias effect estimates either through limiting the contribution of event-free follow-up time or limiting the identification metastatic progression.

Other missing data involved 17 subjects for clinical tumor stage and 23 subjects for percent core positivity, which prevented these observations from contributing to regression and post-matching effect estimation. However, due to the limited number of subjects missing information on these variables, inferences regarding the distribution of missing data are limited and data imputation methods, such as multiple imputation, are unlikely to lead to notably different effect estimates or provide additional information.

The strengths of our study include the comparison of men treated with RT who were also eligible for RP thereby mitigating violations of positivity required for the conduct of regression analysis.\textsuperscript{12} Moreover, systematic identification of comparable treatment groups through propensity score matching and coarsened exact matching has potential to reduce reliance on model specification,\textsuperscript{13} thereby improving the robustness of confounding control. Furthermore, since men were diagnosed between 2007 and 2012 from two large academic centers, treatment approaches are expected to be more consistent with contemporary treatment approaches. Finally, the endpoint employed in this study, metastatic progression-free survival, is a clinically meaningful endpoint, and the only validated surrogate endpoint for overall survival to date in prostate cancer.\textsuperscript{26}
The findings of this study are subject to limitations. First, the proportion of men treated with RT who received ADT was much lower than other similar investigations. Since ADT has been shown to decrease the rate of metastatic progression, the rates observed among men treated with RT in our cohort may exceed those achievable through the current standard of care, which recommends RT and ADT for men diagnosed with unfavorable-risk PCa. In addition, the series of men treated at LHSC may not have been comparable to men treated at GGWPC so there is potential for confounding of effect estimates by treatment center. Finally, due to data limitations, percent of tumor containing biopsy cores, comorbidities, and socioeconomic and demographic characteristics could not be controlled for, potentially biasing effect estimates.

Conclusions
The results from our study support findings from previous analyses that more contemporary forms of treatment involving RT as an initial strategy may be, at least, comparable to those involving initial RP for men diagnosed with unfavorable-risk PCa. Furthermore, the decreased use of salvage therapies among men treated with RT relative to RP may have benefits with regard to fewer side effects in the long-term management of this patient population. Given the limitations of observational data, the results from this study must be interpreted with caution.
References

1. Bray F, Ferlay J, Soerjomataram I, et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. *CA Cancer J Clin* 2018; 68:394–424.

2. Rodrigues G, Lukka H, Warde P, et al. The prostate cancer risk stratification (ProCaRS) project: Recursive partitioning risk stratification analysis. *Radiother Oncol* 2013; 109:204–10. Available from: http://dx.doi.org/10.1016/j.radonc.2013.07.020

3. Beckmann K, Garmo H, Nilsson P, et al. Radical radiotherapy for prostate cancer: patterns of care in Sweden 1998–2016. *Acta Oncol (Madr)* 2020; 59:549–57. Available from: https://doi.org/10.1080/0284186X.2020.1730003

4. Zelefsky M, Reuter V, Fuks Z, et al. Influence of local tumor control on distant metastases and cancer related mortality after external beam radiotherapy for prostate cancer. *J Urol* 2008; 179:1368–73.

5. Bill-Axelson A, Holmberg L, Ruutu M, et al. Radical prostatectomy versus watchful waiting in early prostate cancer. *N Engl J Med* 2011; 364:1708–17.

6. Hamdy F, Donovan J, Lane J, et al. 10-year outcomes after monitoring, surgery, or radiotherapy for localized prostate cancer. *N Engl J Med* 2016; 375:1415–24.

7. Bolla M, van Poppel H, Tombal B, et al. Postoperative radiotherapy after radical prostatectomy for high-risk prostate cancer: long-term results of a randomised controlled trial (EORTC trial 22911). *Lancet* 2018; 380:2018–27.

8. Horwitz E, Bae K, Hanks G, et al. Ten-year follow-up of radiation therapy oncology group protocol 92-02: a phase III trial of the duration of androgen deprivation in locally advanced prostate cancer. *J Clin Oncol* 2008; 26:2497–504.

9. Morris WJ, Tyldesley S, Rodda S, et al. Androgen Suppression Combined with Elective Nodal and Dose Escalated Radiation Therapy (the ASCENDE-RT Trial): An Analysis of Survival Endpoints for a Randomized Trial Comparing a Low-Dose-Rate Brachytherapy Boost to a Dose-Escalated External Beam Boost. *Int J Radiat Oncol Biol Phys* 2017; 98:275–85. Available from: http://dx.doi.org/10.1016/j.ijrobp.2016.11.026

10. Sanda MG, Cadeddu JA, Kirkby E, et al. Clinically Localized Prostate Cancer: AUA/ASTRO/SUO Guideline. Part I: Risk Stratification, Shared Decision Making, and Care Options. *J Urol* 2018; 199:683–90. Available from: https://doi.org/10.1016/j.juro.2017.11.095

11. Petrelli F, Vavassori L, Coim A, et al. Radical prostatectomy or radiotherapy in high-risk prostate cancer: A systematic review and metaanalysis. *Clin Genitourin Cancer* 2014; 12:215–24. Available from: http://dx.doi.org/10.1016/j.clgc.2014.01.010

12. Westreich D, Cole SR. Invited commentary: Positivity in practice. *Am J Epidemiol* 2010; 171:674–7.

13. Ho DE, Imai K, King G, et al. Matching as nonparametric preprocessing for reducing model dependence in parametric causal inference. *Polit Anal* 2007; 15:199–236.

14. Grijalva CG, Roumie CL, Murff HJ, et al. The role of matching when adjusting for baseline differences in the outcome variable of comparative effectiveness studies. *J Comp Eff Res* 2015; 4:341–9.

© 2021 Canadian Urological Association
15. Brookhart MA, Schneeweiss S, Rothman KJ, et al. Variable selection for propensity score models. *Am J Epidemiol* 2006;163:1149–56.

16. Austin PC. Balance diagnostics for comparing the distribution of baseline covariates between treatment groups in propensity-score matched samples. *Stat Med* 2009;3083–107.

17. Ho D, Imai K, King G, et al. MatchIt: Nonparametric Preprocessing for Parametric Causal Inference. *J Stat Softw* 2011;42:1–43.

18. Team Rs. RStudio: Integrated Development Environment for R [Internet]. Boston, MA: RStudio, PBC; 2020. Available from: http://www rstudio.com/

19. Therneau TM, Lumley T, Atkinson E, et al. Package ‘survival’ [Internet]. 2020. p. 1–176. Available from: https://github.com/therneau/survival

20. Gayat E, Resche-rigon M, Mary J. Propensity score applied to survival data analysis through proportional hazards models: a Monte Carlo study. *Pharm Stat* 2012;11:222–9.

21. Kishan A, Cook R, Ciezki J, et al. Radical prostatectomy, external beam radiotherapy, or external beam radiotherapy with brachytherapy boost and disease progression and mortality in patients with Gleason score 9-10 prostate cancer. *JAMA* 2019;319:896–905.

22. Markovina S, Marshall W, Badiyan SN, et al. Superior metastasis-free survival for patients with high-risk prostate cancer treated with definitive radiation therapy compared to radical prostatectomy: A propensity score-matched analysis. *Adv Radiat Oncol* 2017;3:190–6.

23. Reichard C, Hoffman K, Tang C, et al. Radical prostatectomy or radiotherapy for high-and very high-risk prostate cancer: a multidisciplinary prostate cancer clinic experience of patients eligible for either treatment. *BJU Int* 2019;124:811–9.

24. Yin M, Zhao J, Monk P, et al. Comparative effectiveness of surgery versus external beam radiation with/without brachytherapy in high-risk localized prostate cancer. *Cancer Med* 2020;9:27–34.

25. Jayadevappa R, Lee DI, Chhatre S, et al. Comparative effectiveness of treatments for high-risk prostate cancer patients. *Urol Oncol Semin Orig Investig* 2019;37:574.e11-574.e18. Available from: https://doi.org/10.1016/j.urolonc.2019.06.005

26. Gharzai L, Jiang R, Wallington D, et al. Intermediate clinical endpoints for surrogacy in localised prostate cancer: an aggregate meta-analysis. *Lancet Oncol* 2021;22:402–10.

27. Sanda MG, Cadeddu JA, Kirkby E, et al. Clinically Localized Prostate Cancer: AUA/ASTRO/SUO Guideline. Part II: Recommended approaches and details of specific care options. *J Urol* 2018;199:990–7. Available from: https://doi.org/10.1016/j.juro.2018.01.002
Figures and Tables

**Fig. 1.** Kaplan-Meier curve showing the probability of metastatic progression-free survival over time stratified by treatment group. RP: radical prostatectomy; RT: radiation therapy.
Table 1. Descriptive patient and treatment characteristics
### Treatment group

|                      | RT n=164 | RP n=169 | SMD | Variance ratio | GGWPC RP n=75 | LHSC RP n=94 |
|----------------------|----------|----------|-----|----------------|----------------|---------------|
| Followup time (months), median (Q1, Q3) | 83.9 (58.8, 106.3) | 96.9 (67.8, 118.4) | 0.20 | 98.8 (69.3, 124.0) | 94.5 (65.2, 113.1) |
| Metastatic events, n (%) | 20 (12.2) | 33 (19.5) | 0.18 | 0.49 | 11 (14.7) | 22 (23.4) |
| Age at diagnosis, mean (SD) | 72.5 (7.5) | 62.6 (6.4) | 1.42 | 0.74 | 62.1 (6.7) | 63.6 (5.9) |
| Missing n (%) | 3 (1.8) | 0 (0) | 0 (0) | 0 (0) |
| Baseline PSA (ng/ml), mean (SD) | 19.7 (21.9) | 16.4 (15.3) | 0.18 | 0.49 | 14.4 (10.9) | 17.9 (18.0) |
| Missing, n (%) | 1 (0.6) | 0 (0) | 0 (0) | 0 (0) |
| Clinical T stage |
| 1 | 75 (48.4) | 65 (40.1) | 0.17 | 43 (62.3) | 22 (23.7) |
| 2 | 67 (43.2) | 57 (35.2) | 0.17 | 20 (29.0) | 37 (39.8) |
| 3 | 13 (8.4) | 37 (22.8) | 0.41 | 6 (8.7) | 31 (33.3) |
| 4 | 0 (0) | 3 (1.9) | 0.19 | 0 (0) | 3 (3.2) |
| Missing, n (%) | 9 (5.5) | 7 (4.1) | 6 (8.0) | 1 (1.1) |
| Gleason score |
| ≤6 | 4 (2.4) | 5 (3.0) | 0.03 | 2 (2.9) | 3 (3.2) |
| 7 | 108 (65.9) | 103 (61.0) | 0.10 | 46 (66.7) | 55 (58.5) |
| 8 | 20 (12.2) | 31 (18.3) | 0.17 | 7 (10.1) | 22 (23.4) |
| 9 | 32 (19.5) | 28 (16.6) | 0.08 | 14 (20.3) | 13 (13.8) |
| 10 | 0 (0) | 2 (1.2) | 0.15 | 0 (0) | 1 (1.1) |
| Missing, n (%) | 0 (0) | 0 (0) | 0 (0) | 0 (0) |
| (%) core positivity, mean (SD) | 56.4 (27.8) | 51.0 (25) | 0.20 | 0.81 | 50.5 (24.2) | 51.7 (25.6) |
| ≥50% | 97 (59.2) | 93 (59.2) | 0.00 | 39 (56.5) | 48 (63.2) |
| Missing, n (%) | 0 (0) | 12 (7.1) | 0 (0) | 12 (12.8) |
| ProCaRS risk groups |
| High-intermediate | 72 (47.4) | 58 (40.6) | 0.14 | 29 (45.7) | 29 (38.7) |
| High | 48 (31.6) | 59 (41.3) | 0.20 | 27 (39.7) | 32 (42.7) |
| Extremely high | 32 (21.1) | 26 (18.2) | 0.07 | 12 (17.7) | 14 (18.7) |
| Missing, n (%) | 12 (7.3) | 26 (18.4) | 7 (10.4) | 19 (20.2) |

*Patients with insufficient information to classify risk group were either high- or extremely high-risk. ADT: androgen deprivation therapy; EQD2: equivalent dose in 2-Gy fractions; GGWPC: Gale and Graham Wright Prostate Center; LHSC: London Health Sciences Centre; RP: radical prostatectomy; RT: radiation therapy; SMD: absolute standardized mean difference.*
| Table 2. Treatment characteristics |
|-----------------------------------|
| **Radiotherapy patients**         |
| EQD2 for EBRT, median (range)     | GGWPC | LHSC |
| 78 (70, 108.5)                    |       |
| EQD2 for EBRT+BT, median (range)  | GGWPC | LHSC |
| 113.57 (113.1, 116.7)             |       |
| ADT n (%)                         | GGWPC | LHSC |
| 95 (57.9)                         |       |
| Initial ADT, n (%)                | GGWPC | LHSC |
| 67 (40.9)                         |       |
| Duration ADT, median (range)      | GGWPC | LHSC |
| 22.1 (2.5, 43.3)                  |       |
| **Brachytherapy boost type**      |
| Low-dose rate                     | GGWPC | LHSC |
| 1 (0.6)                           |       |
| High-dose rate                    | GGWPC | LHSC |
| 18 (10.6)                         |       |
| **Prostatectomy patients**        |
| Neoadjuvant systemic therapy      | GGWPC | LHSC |
| 40 (23.7)                         | 2 (2.7) | 38 (40.4) |
| Adjuvant radiotherapy             | GGWPC | LHSC |
| 57 (33.7)                         | 9 (12) | 48 (51.1) |
| Adjuvant systemic                 | GGWPC | LHSC |
| 32 (18.9)                         | 8 (10.7) | 24 (25.5) |
| **All patients**                  |
| Local salvage                     | GGWPC | LHSC |
| 0 (0)                             | 52 (30.8) | 36 (48.0) | 16 (17.0) |
| Salvage RT                        | GGWPC | LHSC |
| 14 (8.5)                          | 48 (28.4) | 20 (26.7) | 28 (29.8) |

ADT: androgen deprivation therapy; BT: brachytherapy; EBRT: external beam radiation therapy; EQD2: Equivalent dose in 2-Gy fractions; GGWPC: Gale and Graham Wright Prostate Center; LHSC: London Health Sciences Centre; RT: radiation therapy.
Table 3. Hazards ratios and confidence intervals for metastatic progression in RP relative to RT

|                  | Unadjusted | Adjusted* |            |            |            |            |            |
|------------------|------------|-----------|------------|------------|------------|------------|
|                  | Hazard ratio | 95% CI | p | Hazard ratio | 95% CI | p |
| Unmatched        | 1.29        | 0.74, 2.26 | 0.37 | 1.16        | 0.63, 2.13 | 0.64 |
| PSM              | 1.01        | 0.50, 2.05 | 0.64 | 1.06        | 0.50, 2.26 | 0.87 |
| CEM              | 1.32        | 0.62, 2.82 | 0.47 | 1.55        | 0.60, 3.98 | 0.37 |

*Adjusted model includes baseline prostate-specific antigen (PSA), clinical T stage, and Gleason score as continuous linear variables with interactions between baseline PSA and clinical T stage and baseline PSA and Gleason score. CEM: coarsened exact matched; CI: confidence interval; PSM: propensity score matched; RP: radical prostatectomy; RT: radiation therapy.